|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85 EUR | +0.35% |
|
+7.05% | +41.20% |
| Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Laboratorios Farmaceuticos Rovi, S.A. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 380.85 million compared to EUR 380.4 million a year ago. Net income was EUR 66.65 million compared to EUR 80.62 million a year ago.
Basic earnings per share from continuing operations was EUR 1.25 compared to EUR 1.5 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +41.20% | 4.7B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
LABORATORIOS FARMACEUTICOS ROVI, S.A. 
